Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery

NCT06214533 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma
Liver, Cancer of, Primary Resectable

Interventions

DRUG: Ropivacaine 0.5%
DRUG: Normal Saline

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University